查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
肺部藥物輸送系統市場:各產品類型，各用途，各流通管道，各地區:規模，佔有率，展望，機會分析，2023年～2030年
市場調查報告書
商品編碼
1349949

肺部藥物輸送系統市場:各產品類型，各用途，各流通管道，各地區:規模，佔有率，展望，機會分析，2023年～2030年

Pulmonary Drug Delivery Systems Market, By Product type, By Application, By Distribution Channel, By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 233 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2023 年，全球肺部給藥系統市場將達到 343.4 億美元，預測期內（2023-2030 年）複合年增長率為 4.6%。Masu。

報告範圍 報告詳細資料
基準年 2022 2023 年市場規模 美國：343.4億美元
過去的資料 2018年至2021年 預測期間 2023-2030
預測 2023-2030 年複合年增長率： 4.60% 2030年價值預測 470.5億美元
肺部給藥系統市場-IMG1

肺部給藥是病人使用吸入器吸入藥物，藥物經由肺黏膜吸收到血流中的給藥途徑。肺部給藥在呼吸系統疾病的治療中提供了直接到達病灶的途徑，同時為藥物的全身吸收提供了廣闊的表面積和相對無?的受控環境。

與靜脈、口服、口腔、經皮、陰道、鼻腔和眼部給藥相比，肺部給藥作為治療全身性疾病的給藥途徑具有多種優勢。

市場動態

主要市場參與者正專注於有機成長策略，例如監管產品批准，以擴大其產品組合，預計將在預測期內推動全球肺部藥物輸送系統市場的成長。例如，2020年7月，製藥公司諾華公司宣布，歐盟委員會（EC）已批准Enerzair Breezhaler作為成年患者氣喘的維持治療。此次批准還包括一個可選的數位伴侶，帶有感測器和應用程序，可提供吸入確認、用藥提醒和存取客觀數據，以更好地支持治療決策。

主要市場參與者增加的肺部疾病治療研發活動預計將在預測期內推動市場成長。例如，2020年12月，專注於透過口腔崩解片技術開發治療哮喘和慢性阻塞性肺病等呼吸系統疾病具有根本優勢的先進吸入製劑的Intas Pharmaceuticals Ltd.宣布正在這樣做。此藥物輸送系統專為快速產品崩解而設計，確保更快起效。該技術已用於多種分子，以方便對兒科、老年和精神病呼吸系統患者的給藥，提高患者的依從性，並提供方便的劑量。

本調查的主要特徵

  • 本報告提供以2022年為基準年的預測期間（2023-2030 年）之全球肺部藥物輸送系統市場的市場規模和復合年增長率（CAGR %）相關的詳區隔析。
  • 並闡明不同部門市場的潛在收入機會，說明該市場具有魅力的投資主張矩陣。
  • 同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
  • 並基於企業亮點，各類型投資組合、主要焦點、財務業績和市場策略等參數，介紹全球肺部藥物輸送系統市場的主要參與者之企業簡介。
  • 藉由該報告提供的洞察，將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
  • 全球肺部藥物輸送系統市場報告配合該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
  • 利益相關者可以透過全球肺部藥物輸送系統市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。

目錄

第1章 調查目的與前提條件

  • 調查目的
  • 前提條件
  • 簡稱

第2章 市場概況

  • 報告概要
    • 市場定義和範圍
  • 摘要整理
  • Coherent Opportunity Map(COM)

第3章 市場動態，法規，趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 最近的產品上市
  • 流行病學
  • 合併，收購，聯盟
  • 法規情勢
  • 主要的發展
  • PEST分析
  • 夥伴關係方案
  • 品牌和價格分析
  • 分銷商的形勢
  • 波特分析
  • 技術的進步
  • 主要的發展
  • 市場趨勢

第4章 肺部藥物輸送系統的全球市場-COVID-19影響分析

  • 經濟影響
  • COVID-19流行病學
  • 供需的影響

第5章 肺部藥物輸送系統的全球市場:各產品類型，2018-2030年

  • 噴霧器
  • 乾粉末吸入器(DPI)
  • 定量吸入器(MDI)

第6章 肺部藥物輸送系統的全球市場:各用途，2018～2030年

  • 氣喘
  • 慢性阻塞性肺病（COPD）
  • 囊狀纖維化症
  • 過敏性鼻炎
  • 其他

第7章 肺部藥物輸送系統的全球市場:各流通管道，2018年～2030年

  • 醫院藥局
  • 零售藥局
  • 線上藥局

第8章 肺部藥物輸送系統的全球市場:各地區，2018年～2030年

  • 北美
  • 美國
  • 加拿大
  • 南美
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他南美國家
  • 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太地區
  • 中東
  • GCC
  • 以色列
  • 其他中東
  • 非洲
  • 北非
  • 中非
  • 南非

第9章 競爭情形

  • 3M Health Care
  • Allied Healthcare Products, Inc.
  • AstraZeneca
  • Boehringer Ingelheim International GmbH.
  • CareFusion Corporation
  • GF Health Products, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Omron Healthcare, Inc.
  • Glenmark Pharmaceuticals
  • PARI Respiratory Equipment, Inc.
  • Koninklijke Philips N.V.

第10章 章節

  • 調查手法
  • 關於出版社
簡介目錄
Product Code: CMI3952

The global pulmonary drug delivery systems market is estimated to be valued at US$ 34.34 billion in 2023 and is expected to exhibit a CAGR of 4.6% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 34.34 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 4.60% 2030 Value Projection: US$ 47.05 Bn
Pulmonary Drug Delivery Systems Market - IMG1

Pulmonary drug delivery is a route of administration in which patients use an inhaler to inhale its medications, and drugs are absorbed into the bloodstream via the lung mucous membrane. It provides direct access to disease in the treatment of respiratory diseases, while providing an enormous surface area and a relatively low enzymatic, controlled environment for systemic absorption of medications.

Pulmonary drug delivery offers several advantages as a route of administration for the treatment of systemic diseases compared with intravenous, oral, buccal, transdermal, vaginal, nasal or ocular administration.

Market Dynamics

The key market players are focused on organic growth strategies such as product approval by regulatory authorities to expand its product portfolio is expected to drive the global pulmonary drug delivery systems market growth over the forecast period. For instance, in July 2020, Novartis AG, a pharmaceutical company, announced that the European Commission (EC) has approved Enerzair Breezhaler, as a maintenance treatment of asthma in adult patients. The approval also includes an optional digital companion with sensor and app that provides inhalation confirmation, medication reminders and access to objective data to better support therapeutic decisions.

The increasing research and development activities by key market players for the treatment of pulmonary diseases is expected to drive the market growth over the forecast period. For instance, in December 2020, Intas Pharmaceuticals Ltd., announced that the company was focused on developing advanced inhalation formulation having fundamental advantages in the therapy of diseases of the respiratory tract, including asthma and Chronic Obstructive Pulmonary Disease with Orally Disintegrating Tablet Technology. The Drug delivery system designed for rapid disintegration of the product ensuring faster onset of action. This technology is used for several molecules to facilitate ease of administration and improved patient compliance & convenient dosing for paediatric, geriatric, and psychiatric patients with respiratory diseases.

Key features of the study:

  • This report provides an in-depth analysis of the global pulmonary drug delivery systems market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global pulmonary drug delivery systems marketbased on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca, Boehringer Ingelheim International GmbH., CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., and Koninklijke Philips N.V.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global pulmonary drug delivery systems market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pulmonary drug delivery systems market

Detailed Segmentation:

  • Global Pulmonary Drug Delivery Systems Market, By Product Type:
    • Nebulizers
    • Dry Powder Inhalers (DPIs)
    • Metered Dose Inhalers (MDIs)
  • Global Pulmonary Drug Delivery Systems Market, By Application:
    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Cystic Fibrosis
    • Allergic Rhinitis
    • Others
  • Global Pulmonary Drug Delivery Systems Market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Pulmonary Drug Delivery Systems Market, By Region:
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • 3M Health Care
    • Allied Healthcare Products, Inc.
    • straZeneca
    • Boehringer Ingelheim International GmbH.
    • CareFusion Corporation
    • GF Health Products, Inc.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Novartis AG
    • Omron Healthcare, Inc.
    • Glenmark Pharmaceuticals
    • PARI Respiratory Equipment, Inc.
    • Koninklijke Philips N.V.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Product Type
    • Market Snapshot, By Application
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Recent Product Launches
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis
  • Partnership Scenario
  • Brand and Pricing Analysis
  • Distributors Landscape
  • Porters Analysis
  • Technological Advancements
  • Key Developments
  • Market Trend

4. Global Pulmonary Drug Delivery Systems Market- COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Pulmonary Drug Delivery Systems Market, By Product Type, 2018-2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Nebulizers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Segment Trends
  • Dry Powder Inhalers (DPIs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Segment Trends
  • Metered Dose Inhalers (MDIs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Segment Trends
    • Segment Trends

6. Global Pulmonary Drug Delivery Systems Market, By Application, 2018-2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Asthma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Segment Trends
  • Chronic Obstructive Pulmonary Disease (COPD)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Segment Trends
  • Cystic Fibrosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Segment Trends
  • Allergic Rhinitis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Segment Trends
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
    • Segment Trends

7. Global Pulmonary Drug Delivery Systems Market, By Distribution Channel, 2018-2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospitals Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Million)

8. Global Pulmonary Drug Delivery Systems Market, By Region, 2018-2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Modality, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • 3M Health Care
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Allied Healthcare Products, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Boehringer Ingelheim International GmbH.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • CareFusion Corporation
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • GF Health Products, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • GlaxoSmithKline plc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Omron Healthcare, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Glenmark Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • PARI Respiratory Equipment, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Koninklijke Philips N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

10. Section

  • Research Methodology
  • About Us